Since 2007, the Standing Committee on Vaccination (STIKO) has recommended that all girls receive vaccinations against the human papillomavirus (HPV) in order to reduce the disease burden of cervical cancer. Persistent infections with high-risk HPV subtypes increase a woman’s risk of developing cancer. In the second wave of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS Wave 2, 2014-2017), 42% of 2,958 11- to 17-year-old girls reported that they had received at least one HPV vaccination, and 31.4% reported a full HPV vaccination. 45.3% of 14- to 17-year-old girls reported a complete series of HPV vaccinations. Compared to the figures reported in KiGGS Wave 1 five years ago, HPV vaccination covera...
HPV causes about 5% of all cancers worldwide. The most common of these cancers is cervical but the v...
HPV causes about 5% of all cancers worldwide. The most common of these cancers is cervical but the v...
BACKGROUND The efficacy and effectiveness of the quadrivalent human papillomavirus (HPV) vaccine in ...
Since 2007, the Standing Committee on Vaccination (STIKO) has recommended that all girls receive vac...
Background: Estimates of Human Papillomavirus (HPV) prevalence in a population prior to and after...
Background Human Papillomavirus (HPV) vaccination of girls was introduced in Germany in 2007. Howev...
Objective: The objective of this study is to assess the HPV vaccination coverage of 11-19-year-old g...
Abstract Background Adequate coverage is key to the success of human papillomavirus (HPV) vaccinatio...
Gardasil®, a quadrivalent vaccine targeting low-risk (6, 11) and high-risk (16, 18) human papillomav...
Gardasil®, a quadrivalent vaccine targeting low-risk (6, 11) and high-risk (16, 18) human papillomav...
Human papillomavirus (HPV) vaccines are available in the United States and around the world to preve...
Background: The human papillomavirus (HPV) vaccination program for young girls aged 11⁻26 years was ...
Background: The human papillomavirus (HPV) vaccination program for young girls aged 11⁻26 years was ...
HPV causes about 5% of all cancers worldwide. The most common of these cancers is cervical but the v...
OBJECTIVES The objectives were to measure uptake of and factors associated with human papillomavi...
HPV causes about 5% of all cancers worldwide. The most common of these cancers is cervical but the v...
HPV causes about 5% of all cancers worldwide. The most common of these cancers is cervical but the v...
BACKGROUND The efficacy and effectiveness of the quadrivalent human papillomavirus (HPV) vaccine in ...
Since 2007, the Standing Committee on Vaccination (STIKO) has recommended that all girls receive vac...
Background: Estimates of Human Papillomavirus (HPV) prevalence in a population prior to and after...
Background Human Papillomavirus (HPV) vaccination of girls was introduced in Germany in 2007. Howev...
Objective: The objective of this study is to assess the HPV vaccination coverage of 11-19-year-old g...
Abstract Background Adequate coverage is key to the success of human papillomavirus (HPV) vaccinatio...
Gardasil®, a quadrivalent vaccine targeting low-risk (6, 11) and high-risk (16, 18) human papillomav...
Gardasil®, a quadrivalent vaccine targeting low-risk (6, 11) and high-risk (16, 18) human papillomav...
Human papillomavirus (HPV) vaccines are available in the United States and around the world to preve...
Background: The human papillomavirus (HPV) vaccination program for young girls aged 11⁻26 years was ...
Background: The human papillomavirus (HPV) vaccination program for young girls aged 11⁻26 years was ...
HPV causes about 5% of all cancers worldwide. The most common of these cancers is cervical but the v...
OBJECTIVES The objectives were to measure uptake of and factors associated with human papillomavi...
HPV causes about 5% of all cancers worldwide. The most common of these cancers is cervical but the v...
HPV causes about 5% of all cancers worldwide. The most common of these cancers is cervical but the v...
BACKGROUND The efficacy and effectiveness of the quadrivalent human papillomavirus (HPV) vaccine in ...